Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Shandong University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination therapy consists of albumin-bound paclitaxel (nab-paclitaxel) and a bevacizumab biosimilar. Nab-paclitaxel is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization, which inhibits mitosis and leads to cell death. Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), preventing its interaction with receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells. This action inhibits tumor angiogenesis, thereby limiting the blood supply necessary for tumor growth and metastasis. The specific combination is being investigated by Shandong University in a Phase II clinical trial for patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not previously received bevacizumab therapy.
- Brand names
- Abraxane
- Other names
- nab-paclitaxel + bevacizumabAbraxane + bevacizumab biosimilar
02
Targets
VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on albumin-bound paclitaxel + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + bevacizumab.